Through the first three quarters of 2022, sales of the biopharmaceutical industry’s top products were largely at a steady state except for COVID-19 products, where the antiviral for infected patients became the top seller in the third quarter while vaccines that held the top two spots during each of the first two quarters declined sharply.
Not among the 10 highest-selling drugs during the first quarter of 2022, Pfizer Inc.’s Paxlovid (nirmatrelvir/ritonavir) rose to second...







